CN110108877B

CN110108877B - Application of FAM172A autoantibody detection reagent in preparation of lung cancer screening kit

Info

Publication number: CN110108877B
Application number: CN201910466523.8A
Authority: CN
Inventors: 张立; 李为民
Original assignee: West China Hospital of Sichuan University
Current assignee: West China Hospital of Sichuan University
Priority date: 2019-05-30
Filing date: 2019-05-30
Publication date: 2020-06-16
Anticipated expiration: 2039-05-30
Also published as: CN110108877A

Abstract

The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a FAM172A autoantibody detection reagent in preparation of a lung cancer screening kit. The invention discovers for the first time that the level of autoantibodies of FAM172A protein in the serum of a lung cancer patient is obviously higher than that of a healthy patient. According to the invention, the reagent for detecting the FAM172A protein autoantibody is used for preparing the lung cancer screening kit, so that effective screening of lung cancer can be realized.

Description

Application of FAM172A autoantibody detection reagent in preparation of lung cancer screening kit

Technical Field

The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a FAM172A autoantibody detection reagent in preparation of a lung cancer screening kit.

Background

Lung cancer is one of the most common malignant tumors in the world, the morbidity and mortality of the lung cancer are on the rising trend year by year, the morbidity is at the top of the world at present, and the health and the life of human beings are seriously threatened.

The lung cancer is a disease good in occult, clinical symptoms are often shown only when the disease develops to the advanced stage, 70-80% of lung cancer patients are already at the middle and advanced stages when the lung cancer symptoms are diagnosed, cancer cells are diffused, the best curing time is missed, and the five-year survival rate is low. For early-stage lung cancer patients, the survival rate and the survival quality of the patients can be greatly improved by 5 years and more through timely treatment. Early diagnosis of lung cancer and effective screening are therefore of paramount importance.

The screening of the lung cancer refers to that the conventional physical examination is carried out on people without lung cancer related symptoms, and the lung cancer is found in time before the symptoms appear. If the lung cancer molecular marker in the plasma can be found, the molecular marker has important significance for prompting a clinician to take relevant treatment measures or decisions for a patient at an early stage.

Autoantibodies are antibodies produced by the body to self-organs, cells or cellular components. At present, autoantibodies to certain proteins have become markers for lung cancer, such as: p53, NY-ESO-1, CYFRA, etc. (Tang Z-M, Link Z-G, WangC-M, Wu Y-B, Kong J-L (2017) Serum tune-associated autoimmune agents as diagnostic biologics for lung cancer: A systematic review and meta-analysis. PLoS ONE 12 (7): e 0182117).

FAM172A (Ensembl: ENSG00000113391) protein has been reported to be involved in cancer, for example, it can aggravate development of papillary thyroid cancer (FAM172A protein proteins of the promotion of papillary thyroid cancer cells of the p38 mitogen-activated protein kinase pathway. mol Med. Rep. Jan; 13 (1): 353-8.), and also can be used as an anti-cancer factor for colorectal cancer (FAM172A a promoter in general cancer. Tumour biol. 2016May; 37 (5): 6501-10.). However, reports related to FAM172A protein autoantibodies are not found at present, and the prior art related to lung cancer is not found.

Disclosure of Invention

The invention aims to provide a novel autoantibody lung cancer marker and application of a detection reagent of the marker in preparation of a lung cancer screening kit.

The technical scheme of the invention comprises the following steps:

the application of the reagent for detecting the FAM172A protein autoantibody in preparing a lung cancer screening kit.

As the application, the reagent for detecting the FAM172A protein autoantibody is a reagent for enzyme-linked immunosorbent assay or a combined immunoassay reagent.

As for the application, the reagent for detecting the FAM172A protein autoantibody is a western blot reagent.

As mentioned above, the reagent for detecting FAM172A protein autoantibody is a reagent for protein chip detection method.

As for the application, the reagent for detecting the FAM172A protein autoantibody is a reagent for detecting the FAM172A protein autoantibody in human serum.

A lung cancer screening kit, which comprises a reagent for detecting FAM172A protein autoantibody.

As the kit, the reagent for detecting the FAM172A protein autoantibody is a reagent for enzyme-linked immunosorbent assay or an enzyme-linked immunoassay reagent.

As the kit, the reagent for detecting the FAM172A protein autoantibody is a western blot reagent.

As the kit, the reagent for detecting the FAM172A protein autoantibody is a reagent for a protein chip detection method.

As the kit, the reagent for detecting the FAM172A protein autoantibody is a reagent for detecting the FAM172A protein autoantibody in human serum.

The invention provides a new lung cancer screening marker and a new lung cancer screening kit, which can realize effective screening of lung cancer; and the serum can be used as a detection sample, so that the harm to a patient is low. The invention has good application prospect.

Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.

The foregoing aspects of the present invention are explained in further detail below with reference to specific embodiments. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.

Hereinafter, "FAM 172A autoantibody" refers to "FAM 172A protein autoantibody".

Drawings

FIG. 1: lung cancer patients (LC), benign lung Disease (DC), healthy control (NC) plasma levels of FAM172A autoantibodies were compared.

FIG. 2: ROC analysis of lung cancer patients (LC) and benign lung Disease (DC).

FIG. 3: lung cancer patients (LC) were analyzed by ROC with healthy controls (NC).

Detailed Description

Example 1 relationship between FAM172A autoantibodies and Lung cancer in plasma

First, clinical data

30 lung cancer patients, 29 lung benign diseases (non-malignant tumors such as tuberculosis and hamartoma) and 30 healthy controls are selected, and the basic information is as follows:

second, detection principle

HuProt^TMThe human protein customizing chip is fixed with FAM172A protein, after the human protein customizing chip is incubated by adding serum, FAM172A autoantibodies (mainly comprising IgG and IgM antibodies and also some other types of antibodies) in the serum can be combined, the unbound antibodies and other proteins are removed by cleaning, an anti-human IgM fluorescent labeled secondary antibody (cy5 labeled and red) and an anti-human IgG fluorescent secondary antibody (cy3 labeled and green) are used for detection, signals are read by a fluorescence scanner, and the strength of the signals is positively correlated with the affinity and the quantity of the antibodies.

Third, method

1) Rewarming: taking out the chip from a refrigerator at-80 deg.C, putting in a refrigerator at 4 deg.C for rewarming for half an hour, and then putting in room temperature for rewarming for 15 min;

2) and (3) sealing: fixing 14 blocks in the rewarming chip, adding sealing liquid into each block after fixing, placing on a side swing bed, and sealing at room temperature for 3 hr;

3) incubation of serum samples: after sealing is finished, pouring the sealing liquid completely, then quickly adding a serum incubation liquid prepared in advance, wherein each chip can incubate 14 serum samples, the sample loading volume of each serum sample is 200 mu L, and the shaking table is laterally swung at 20rpm and incubated overnight at 4 ℃ (the serum samples are firstly put in a chromatography cabinet at 4 ℃ for freeze thawing, and the incubation liquid is added to dilute in a ratio of 1: 50 to obtain the serum incubation liquid);

4) cleaning: the chip and the chip fence are taken out together, the sample is sucked, then the PBST with the same volume is added rapidly, and the cycle is repeated for a plurality of times, so that no cross contamination exists among the serum samples when the chip fence is detached. After the chip fence is removed, the chip is placed in a chip cleaning box with cleaning solution, and is cleaned for 3 times (10 min each time) by a horizontal shaking table at room temperature of 80 rpm;

5) and (3) secondary antibody incubation: transferring the chip into an incubation box added with 3mL of secondary antibody incubation liquid, laterally swinging a shaker at 40rpm, keeping out of the sun, and keeping at room temperature for 1 hr;

6) cleaning: the chip was removed (note that the upper surface of the chip was not touched or scratched), and placed in a chip washing cassette containing a washing solution, and washed 3 times 10min each time, on a horizontal shaker at room temperature and 80 rpm. After the completion, the mixture is washed for 2 times for 10min by ddH 2O;

7) drying;

8) scanning: scanning by using a crystal core LuxScan 10K microarray chip scanner;

9) data extraction: opening the corresponding GAL file (recording the position of protein in the chip), aligning the chip image and each array of the GAL file integrally, pressing an automatic alignment button, extracting data and storing.

Fourthly, the result

The mean expression level of FAM172A autoantibodies in the plasma of lung cancer patients was 45.95 SNR (fluorescence signal relative quantitative ratio), the mean expression level of FAM172A autoantibodies in the plasma of benign lung disease was 30.61 SNR, and the mean expression level of FAM172A autoantibodies in the plasma of healthy control was 27.38 SNR. The lung cancer group was statistically significant compared to the benign lung disease group (p < 0.05) and the healthy control group (p < 0.05) (FIG. 1). The specificity of ROC analysis of lung cancer group and benign disease was 96.5%, and the sensitivity was 13.8% (FIG. 2); the results of ROC analysis of lung cancer groups versus healthy controls gave specificity of 96.5% and sensitivity of 27.6% (FIG. 3), indicating that FAM172A autoantibodies specifically distinguished lung cancer from benign lung disease versus healthy controls.

From the above results, it is clear that the difference in the level of FAM172A autoantibodies in the serum of lung cancer patients and non-lung cancer patients is significant, and the purpose of lung cancer screening can be achieved by detecting the level of FAM172A autoantibodies in the serum.

EXAMPLE 2 composition of the detection kit of the invention and method of use thereof

Kit composition

Detection kit (14 persons):

second, kit using method

Same as example 1, third part- "detection of FAM172A autoantibodies in serum".

The kit can screen the risk of lung cancer of a human to be detected by detecting the level of the FAM172A autoantibody in serum: the risk of lung cancer is high if FAM172A autoantibody levels are high (relative to healthy humans), and low if FAM172A autoantibody levels are low. The method can be used for the auxiliary diagnosis of clinical lung cancer, provides effective basis for patients to take relevant treatment measures or decisions, and has good clinical application prospect.

Claims

1. The application of a reagent for detecting FAM172A protein autoantibody in preparing a lung cancer screening kit;

the kit takes FAM172A autoantibody as a unique lung cancer marker;

the autoantibodies are IgM and IgG;

the kit takes serum as a detection sample.

2. The use according to claim 1, wherein the reagent for detecting the FAM172A protein autoantibody is a reagent for enzyme-linked immunosorbent assay.

3. The use according to claim 1, wherein the reagent for detecting the FAM172A protein autoantibody is a western blot reagent.

4. The use according to claim 1, wherein the reagent for detecting the FAM172A protein autoantibody is a reagent for a protein chip detection method.